

Table SI. Percentage suppression in imiquimod (IMQ)-induced skin swelling and hyperplasia by pretreatment of 8-methoxypsoralen plus ultraviolet A (PUVA) or ultraviolet B (UVB)

Groups	Treatment type and days	Percentage suppression by PUVA/UVB		
		Macroscopic skin swelling	Increase in epidermal layers	Increase in epidermal thickness
<i>PUVA</i>				
4PUVA+3D+IMQ (II)	Day 15	74.4		
	Day 16	59.1		
	Day 17	55.1		
	Days 15–18 (mean)	62.9*	45.3	58.1
4PUVA+7D+IMQ (III)	Day 19	32.6		
	Day 20	18.2		
	Day 21	30.6		
	Days 19–21 (mean)	27.1*	16.2	15.6
<i>UVB</i>				
4UVB+3D+IMQ (IX)	Day 15	9.5		
	Day 16	33.3		
	Day 17	25		
	Days 15–18 (mean)	22.6	25.3	48.5
4UVB+7D+IMQ (X)	Day 19	-61.9		
	Day 20	-3		
	Day 21	0		
	Days 19–21 (mean)	-21.6	-15.9	-5.1

Effectiveness of PUVA vs. UVB therapy was determined by calculating the percentage suppression observed in macroscopic (skin swelling) and microscopic (epidermal thickness/layers) parameters, as outlined in the Materials and Methods section. For **p*-values of comparisons among individual groups and days, see Fig. 2.